The study suggests the proportions of Chinese patients with reflux esophagitis rise up with the increase of GerdQ score, and GerdQ may be used for diagnosis of GERD. However, low GerdQ score cannot exclude the possibility of reflux esophagitis. A minority of Chinese patients has high GerdQ score but is diagnosed with malignancies, even in the absence of alarm features.

Background. Functional gastrointestinal disorders (FGIDs) are common in the general population worldwide. However, there is paucity of large sale surveys for prevalence of FGID in the military personnel. Methods. It is a cross-sectional study, using Rome III criteria for the diagnosis of FGID among the Chinese Air Force (CAF) workers. Results. Of 4633 registered male subjects, there were 818 (16.4%) air crew and 4170 (83.6%) ground personnel. FGIDs were identified in 1088 (23.48%) of cases. It was more prevalent in the ground personnel than air crew (24.02% versus 20.33%; P = 0.022). Based on Rome III criteria, the commonest disease category was functional gastroduodenal disorder (37.4%), whereas functional nausea and vomiting disorder (FNV) was the most frequent overall diagnosis. Functional dyspepsia (FD) with irritable bowel syndrome (IBS) was the leading FGIDs' overlap (3.9%). Conclusion. FGIDs in CAF population are rather underestimated. This necessitates preventive strategies according to job characteristics.

ABSTRACT. Pyogenic hepatic abscess (PHA) is a rare but potentially serious disease. Investigations of new therapeutic methods urgently need experimental support in corresponding animal models. However, to date, few studies have evaluated PHA in the minipig. The linear regression equation of the Staphylococcus aureus ATCC 25923 strain was established. PHA was successfully mocked, and S. aureus ATCC 29213 was the only pathogenic bacterium identified. The abscess formation stage was observed on the 21st day of the operation. This study will provide a baseline for further studies evaluating new treatment methods for PHA.

The regression of cirrhosis is associated with increased intrahepatic collagenolytic enzyme activity. We investigated whether collagenase supplementation via portal vein infusion can retard cirrhosis development and/or reverse cirrhosis. In all, 35 rabbits were initially assigned to study. However, because of high surgical mortality and infection, only 15 animals completed study. Four normal controls (group I) received olive oil subcutaneously (SC) for 12 weeks followed by normal saline portal perfusion for 12 weeks. Four (group II) received CCl 4 SC for 6 weeks followed by portal vein collagenase, 6 mg twice weekly, plus SC CCl 4 for 6 additional weeks and then killed. Four rabbits (group III) received CCl 4 SC for 12 weeks and then 6 mg of collagenase portally for 12 weeks, while three control rabbits (group IV) received CCl 4 for 12 weeks followed by saline for 12 weeks. After 12 weeks of CCl 4 , liver hydroxyproline content of collagenase-treated group II (361.17106.6 lg/g) was significantly reduced compared with group III þ IV that had not yet received collagenase (589.07162.9 lg/g; Po0.05). In the main comparison, hydroxyproline content of collagenase-treated group III (177.5735.6 lg/g) was significantly decreased compared with saline-treated controls (446.37150.1 lg/g; Po0.01). Further, liver histology showed complete regression of cirrhosis in the collagenase-treated animals. No toxicity of liver, kidney, lung, brain or heart was observed histologically. Anaphylaxis occurred in 2/35 original animals (one fatal). In conclusion, this study provides 'proof of principle' that collagenase portal administration can retard cirrhosis development and speed regression of established cirrhosis in the rabbit CCl 4 model. Potential application to humans is premature, but feasible, if these findings are confirmed in additional animal studies. Laboratory Investigation (2005) 85, 992-1002.

Aims: To assess the long-term efficacy and safety of single-donor, low-intensity fecal microbiota transplantation (FMT) in treating ulcerative colitis (UC), and to identify the outcome-specific gut bacteria.Design: Thirty-one patients with active UC (Mayo scores ≥ 3) were recruited, and all received FMT twice, at the start of the study and 2∼3 months later, respectively, with a single donor and a long-term follow-up. The fecal microbiome profile was accessed via 16S rRNA sequencing before and after FMT.Results: After the first FMT, 22.58% (7/31) of patients achieved clinical remission and endoscopy remission, with the clinical response rate of 67.74% (21/31), which increased to 55% (11/20) and 80% (16/20), respectively, after the second FMT. No serious adverse events occurred in all patients. During 4 years of follow-up, the mean remission period of patients was 26.5 ± 19.98 m; the relapse rate in the 12 remission patients was 33.33% within 1 year, and 58.3% within 4 years. At baseline, UC patients showed an enrichment in some proinflammatory microorganisms compared to the donor, such as Bacteroides fragilis, Clostridium difficile, and Ruminococcus gnavus, and showed reduced amounts of short-chain fatty acid (SCFA) producing bacteria especially Faecalibacterium prausnitzii. FMT induced taxonomic compositional changes in the recipient gut microbiota, resulting in a donor-like state. Given this specific donor, UC recipients with different outcomes showed distinct gut microbial features before and after FMT. In prior to FMT, relapse was characterized by higher abundances of Bacteroides fragilis and Lachnospiraceae incertae sedis, together with lower abundances of Bacteroides massiliensis, Roseburia, and Ruminococcus; Prevotella copri was more abundant in the non-responders (NR); and the patients with sustained remission (SR) had a higher abundance of Bifidobacterium breve. After FMT, the NR patients had a lower level of Bifidobacterium compared to those with relapse (Rel) and SR, while a higher level of Bacteroides spp. was observed in the Rel group.Conclusion: Low-intensity single donor FMT could induce long remission in active UC. The gut microbiota composition in UC patients at baseline may be predictive of therapeutic response to FMT.